Description
BI-765063 is under investigation for the treatment of colorectal cancer but has not yet been approved by regulatory agencies; its efficacy and safety are currently being evaluated in clinical trials, particularly in patients with mutations affecting Wnt/ -catenin signaling pathway.
Mechanism of Action
BI-765063 is an investigational agent that targets the Wnt/ -catenin signaling pathway, which is frequently dysregulated in colorectal cancer; it inhibits ?-catenin stabilization and degradation.
Side Effects
Fatigue; nausea; diarrhea; vomiting; neutropenia; thrombocytopenia
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT05446129
Phase 1
Archived
A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in Surgery
United States